Associations of fibroblast growth factor-23 with markers of inflammation, insulin resistance and obesity in adults

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Hanks, Lynae J ^a   Casazza, Krista ^a   Judd, Suzanne E ^b   Jenny, Nancy S ^c   Gutiérrez, Orlando M ^d  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^d University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; FIBROBLAST GROWTH FACTOR 23; INTERLEUKIN 10; INTERLEUKIN 6; BIOLOGICAL MARKER; FIBROBLAST GROWTH FACTOR;

ADULT; ALCOHOL CONSUMPTION; ANTHROPOMETRY; ARTICLE; BLACK PERSON; BODY MASS; CAUCASIAN; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; FEMALE; HUMAN; INFLAMMATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; MINERAL METABOLISM; OBESITY; PHLEBOTOMY; PHYSICAL ACTIVITY; WAIST CIRCUMFERENCE; AGED; BLOOD; CHRONIC KIDNEY FAILURE; COMPLICATION; MIDDLE AGED; MULTIVARIATE ANALYSIS;

ADULT; AGED; ANTHROPOMETRY; BIOMARKERS; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; INFLAMMATION; INSULIN RESISTANCE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OBESITY; RENAL INSUFFICIENCY, CHRONIC;

EID: 84926500864     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0122885     Document Type: Article

References (43)

1. Liu S, Quarles LD. How fibroblast growth factor 23 works. J Am Soc Nephrol. 2007 Jun 18: 1637-1647. PMID: 17494882
2. Juppner H, Wolf M, Salusky IB. FGF-23: More than a regulator of renal phosphate handling? J Bone Miner Res. 2010 Oct 25: 2091-2097. doi: 10.1002/jbmr.170 PMID: 20593414
3. Fliser D, Kollerits B, Neyer U, Ankerst DP, Lhotta K, Lingenhel A, et al. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol. 2007 Sep 18: 2600-2608. PMID: 17656479
4. Gutierrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008 Aug 7; 359: 584-592. doi: 10.1056/NEJMoa0706130 PMID: 18687639
5. Isakova T, Xie H, Yang W, Xie D, Anderson AH, Scialla J, et al. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA. 2011 Jun 15; 305: 2432-2439. doi: 10.1001/jama.2011.826 PMID: 21673295
6. Jean G, Terrat JC, Vanel T, Hurot JM, Lorriaux C, Mayor B, et al. High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients. Nephrol Dial Transplant. 2009 Sep 24: 2792-2796. doi: 10.1093/ndt/gfp191 PMID: 19395730
7. Parker BD, Schurgers LJ, Brandenburg VM, Christenson RH, Vermeer C, Kettler M, et al. The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study. Ann Intern Med. 2010 May 18; 152: 640-648. doi: 10.7326/ 0003-4819-152-10-201005180-00004 PMID: 20479029
8. Seiler S, Heine GH, Fliser D. Clinical relevance of FGF-23 in chronic kidney disease. Kidney Int. 2009 Dec Suppl: S34-42.
9. Wojcik M, Dolezal-Oltarzewska K, Janus D, Drozdz D, Sztefko K, Starzyk JB. FGF23 contributes to insulin sensitivity in obese adolescents-preliminary results. Clin Endocrinol. 2012 Oct (Oxf) 77: 537-540. doi: 10.1111/j.1365-2265.2011.04299.x PMID: 22103239
10. Wojcik M, Janus D, Dolezal-Oltarzewska K, Drozdz D, Sztefko K, Starzyk JB. The association of FGF23 levels in obese adolescents with insulin sensitivity. J Pediatr Endocrinol Metab. 2012 25: 687-690. PMID: 23155694
11. Garland JS, Holden RM, Ross R, Adams MA, Nolan RL, Hopman WM, et al. Insulin resistance is associated with Fibroblast Growth Factor-23 in stage 3-5 chronic kidney disease patients. J Diabetes Complications. 2014 Jan-Feb 28: 61-65. doi: 10.1016/j.jdiacomp.2013.09.004 PMID: 24125760
12. Munoz Mendoza J, Isakova T, Ricardo AC, Xie H, Navaneethan SD, Anderson AH, et al. Fibroblast growth factor 23 and Inflammation in CKD. Clin J Am Soc Nephrol. 2012 Jul 7: 1155-1162. doi: 10.2215/CJN.13281211 PMID: 22554719
13. Gutierrez OM, Wolf M, Taylor EN. Fibroblast growth factor 23, cardiovascular disease risk factors, and phosphorus intake in the health professionals follow-up study. Clin J Am Soc Nephrol. 2011 Dec 6: 2871-2878. doi: 10.2215/CJN.02740311 PMID: 22034506
14. Mirza MA, Alsio J, Hammarstedt A, Erben RG, Michaelsson K, Tivesten A, et al. Circulating fibroblast growth factor-23 is associated with fat mass and dyslipidemia in two independent cohorts of elderly individuals. Arterioscler Thromb Vasc Biol. 2011 Jan 31: 219-227. doi: 10.1161/ATVBAHA.110.214619 PMID: 20966399
15. Howard VJ, Cushman M, Pulley L, Gomez CR, Go RC, Prineas RJ, et al. The reasons for geographic and racial differences in stroke study: objectives and design. Neuroepidemiology. 2005 25: 135-143. PMID: 15990444
16. Zakai NA, Judd SE, Alexander K, McClure LA, Kissela BM, Howard G, et al. ABO blood type and stroke risk: the REasons for Geographic And Racial Differences in Stroke Study. J Thromb Haemost. 2014 Apr 12: 564-570. doi: 10.1111/jth.12507 PMID: 24444093
17. Alexander KS, Zakai NA, Gillett S, McClure LA, Wadley V, Unverzagt F, et al. ABO blood type, factor VIII, and incident cognitive impairment in the REGARDS cohort. Neurology. 2014 Sep 30; 83: 1271-1276. doi: 10.1212/WNL.0000000000000844 PMID: 25209581
18. Cushman M, McClure LA, Howard VJ, Jenny NS, Lakoski SG, Howard G. Implications of increased C-reactive protein for cardiovascular risk stratification in black and white men and women in the US. Clin Chem. 2009 Sep 55: 1627-1636. doi: 10.1373/clinchem.2008.122093 PMID: 19643839
19. Gillett SR, Boyle RH, Zakai NA, McClure LA, Jenny NS, Cushman M. Validating laboratory results in a national observational cohort study without field centers: The Reasons for Geographic and Racial Differences in Stroke cohort. Clin Biochem. 2014 Aug 14.
20. Suzuki T, Voeks J, Zakai NA, Jenny NS, Brown TM, Safford MM, et al. Metabolic Syndrome, C-Reactive Protein, and Mortality in U.S. Blacks and Whites: The Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study. Diabetes Care. 2014 Aug 37: 2284-2290. doi: 10.2337/dc13-2059 PMID: 24879838
21. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985 Jul 28: 412-419. PMID: 3899825
22. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009 May 5; 150: 604-612. PMID: 19414839
23. Barlow WE, Ichikawa L, Rosner D, Izumi S. Analysis of case-cohort designs. J Clin Epidemiol. 1999 Dec 52: 1165-1172. PMID: 10580779
24. Mirza MA, Larsson A, Melhus H, Lind L, Larsson TE. Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population. Atherosclerosis. 2009 Dec 207: 546-551. doi: 10.1016/j.atherosclerosis.2009.05.013 PMID: 19524924
25. Donate-Correa J, Muros-de-Fuentes M, Mora-Fernandez C, Navarro-Gonzalez JF. FGF23/Klotho axis: phosphorus, mineral metabolism and beyond. Cytokine Growth Factor Rev. 2012 Feb-Apr 23: 37-46. doi: 10.1016/j.cytogfr.2012.01.004 PMID: 22360923
26. Manghat P, Fraser WD, Wierzbicki AS, Fogelman I, Goldsmith DJ, Hampson G. Fibroblast growth factor-23 is associated with C-reactive protein, serum phosphate and bone mineral density in chronic kidney disease. Osteoporos Int. 2010 Nov 21: 1853-1861. doi: 10.1007/s00198-009-1142-4 PMID: 20012018
27. Dai B, David V, Martin A, Huang J, Li H, Jiao Y, et al. A comparative transcriptome analysis identifying FGF23 regulated genes in the kidney of a mouse CKD model. PLoS One. 2012 7: e44161. doi: 10.1371/journal.pone.0044161 PMID: 22970174
28. Hasegawa H, Nagano N, Urakawa I, Yamazaki Y, Iijima K, Fujita T. Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease. Kidney Int. 2010 78: 975-980. doi: 10.1038/ki.2010.313 PMID: 20844473
29. Shimada T, Urakawa I, Isakova T, Yamazaki Y, Epstein M, Wesseling-Perry K, et al. Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active. J Clin Endocrinol Metab. 2010 Feb 95: 578-585. doi: 10.1210/jc.2009-1603 PMID: 19965919
30. Kovesdy CP, Quarles LD. Fibroblast growth factor-23: what we know, what we don't know, and what we need to know. Nephrol Dial Transplant. 2013 Sep 28: 2228-2236. doi: 10.1093/ndt/gft065 PMID: 23625971
31. Gao D, Trayhurn P, Bing C (2013) 1,25-Dihydroxyvitamin D3 inhibits the cytokine-induced secretion of MCP-1 and reduces monocyte recruitment by human preadipocytes. Int J Obes (Lond) 37: 357-365. doi: 10.1038/ijo.2012.53 PMID: 22508334
32. Wahl P, Xie H, Scialla J, Anderson CA, Bellovich K, Brecklin C, et al. Earlier onset and greater severity of disordered mineral metabolism in diabetic patients with chronic kidney disease. Diabetes Care. 2012 May 35: 994-1001. doi: 10.2337/dc11-2235 PMID: 22446176
33. Chen BH, Song Y, Ding EL, Roberts CK, Manson JE, Rifai N, et al. Circulating levels of resistin and risk of type 2 diabetes in men and women: results from two prospective cohorts. Diabetes Care. 2009 Feb 32: 329-334. doi: 10.2337/dc08-1625 PMID: 18957529
34. Fernandez-Real JM, Puig J, Serrano M, Sabater M, Rubio A, Moreno-Navarrete JM, et al. Iron and obesity status-associated insulin resistance influence circulating fibroblast-growth factor-23 concentrations. PLoS One. 2013 8: e58961. doi: 10.1371/journal.pone.0058961 PMID: 23555610
35. Hesse M, Frohlich LF, Zeitz U, Lanske B, Erben RG. Ablation of vitamin D signaling rescues bone, mineral, and glucose homeostasis in Fgf-23 deficient mice. Matrix Biol. 2007 Mar 26: 75-84. PMID: 17123805
36. Streicher C, Zeitz U, Andrukhova O, Rupprecht A, Pohl E, Larsson TE, et al. Long-term Fgf23 deficiency does not influence aging, glucose homeostasis, or fat metabolism in mice with a nonfunctioning vitamin D receptor. Endocrinology. 2012 Apr 153: 1795-1805. doi: 10.1210/en.2011-1878 PMID: 22294750
37. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, et al. The hormone resistin links obesity to diabetes. Nature. 2001 Jan 18; 409: 307-312. PMID: 11201732
38. Curat CA, Wegner V, Sengenes C, Miranville A, Tonus C, Busse R, et al. Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. Diabetologia. 2006 Apr 49: 744-747. PMID: 16496121
39. Vanholder R, De Smet R, Glorieux G, Argiles A, Baurmeister U, Brunet P, et al. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int. 2003 May 63: 1934-1943. PMID: 12675874
40. Diez JJ, Iglesias P, Fernandez-Reyes MJ, Aguilera A, Bajo MA, Alvarez-Fidalgo P, et al. Serum concentrations of leptin, adiponectin and resistin, and their relationship with cardiovascular disease in patients with end-stage renal disease. Clin Endocrinol. 2005 Feb (Oxf) 62: 242-249. PMID: 15670203
41. Widjaja A, Kielstein JT, Horn R, von zur Muhlen A, Kliem V, Brabant G. Free serum leptin but not bound leptin concentrations are elevated in patients with end-stage renal disease. Nephrol Dial Transplant. 2000 Jun 15: 846-850. PMID: 10831639
42. Harris TB, Visser M, Everhart J, Cauley J, Tylavsky F, Fuerst T, et al. Waist circumference and sagittal diameter reflect total body fat better than visceral fat in older men and women. The Health, Aging and Body Composition Study. Ann N Y Acad Sci. 2000 Jun 904: 462-473. PMID: 10865790
43. Hill JO, Sidney S, Lewis CE, Tolan K, Scherzinger AL, Stamm ER. Racial differences in amounts of visceral adipose tissue in young adults: the CARDIA (Coronary Artery Risk Development in Young Adults) study. Am J Clin Nutr. 1999 Mar 69: 381-387. PMID: 10075320